We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aid Group MPP Negotiates Royalty-Free License on BMS’ Hepatitis C Drug Daklinza
Aid Group MPP Negotiates Royalty-Free License on BMS’ Hepatitis C Drug Daklinza
An international aid group has negotiated a multi-year licensing agreement with Bristol-Myers Squibb to produce generic hepatitis C medicines in many developing nations.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor